GB2063469A - A conjugate for use in an immunoassay procedure - Google Patents
A conjugate for use in an immunoassay procedure Download PDFInfo
- Publication number
- GB2063469A GB2063469A GB8033401A GB8033401A GB2063469A GB 2063469 A GB2063469 A GB 2063469A GB 8033401 A GB8033401 A GB 8033401A GB 8033401 A GB8033401 A GB 8033401A GB 2063469 A GB2063469 A GB 2063469A
- Authority
- GB
- United Kingdom
- Prior art keywords
- conjugate
- tag
- antibody
- porphyrin
- attached
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000003018 immunoassay Methods 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 title claims description 28
- 239000000427 antigen Substances 0.000 claims abstract description 20
- 102000036639 antigens Human genes 0.000 claims abstract description 20
- 108091007433 antigens Proteins 0.000 claims abstract description 20
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 14
- 238000006243 chemical reaction Methods 0.000 claims abstract description 14
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 14
- 150000004032 porphyrins Chemical class 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 9
- 102000018832 Cytochromes Human genes 0.000 claims abstract description 7
- 108010052832 Cytochromes Proteins 0.000 claims abstract description 7
- 108010062374 Myoglobin Proteins 0.000 claims abstract description 7
- 238000001514 detection method Methods 0.000 claims abstract description 7
- 210000001124 body fluid Anatomy 0.000 claims abstract description 5
- 239000010839 body fluid Substances 0.000 claims abstract description 5
- 238000011002 quantification Methods 0.000 claims abstract description 5
- 230000001588 bifunctional effect Effects 0.000 claims abstract description 4
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 4
- 102000036675 Myoglobin Human genes 0.000 claims abstract 3
- 238000009739 binding Methods 0.000 claims description 13
- JQRLYSGCPHSLJI-UHFFFAOYSA-N [Fe].N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 Chemical compound [Fe].N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 JQRLYSGCPHSLJI-UHFFFAOYSA-N 0.000 claims description 12
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 230000001900 immune effect Effects 0.000 claims description 6
- 229910052742 iron Inorganic materials 0.000 claims description 5
- 239000000376 reactant Substances 0.000 claims description 5
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 2
- 102000001554 Hemoglobins Human genes 0.000 claims description 2
- 108010054147 Hemoglobins Proteins 0.000 claims description 2
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 claims description 2
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims 1
- 239000007795 chemical reaction product Substances 0.000 abstract 1
- 239000004677 Nylon Substances 0.000 description 17
- 229920001778 nylon Polymers 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 239000003153 chemical reaction reagent Substances 0.000 description 15
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 15
- 239000011324 bead Substances 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 239000012491 analyte Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 8
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 8
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 7
- 239000007790 solid phase Substances 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000003127 radioimmunoassay Methods 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 241000283707 Capra Species 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 238000012875 competitive assay Methods 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical group OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 102100030856 Myoglobin Human genes 0.000 description 4
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- 239000007975 buffered saline Substances 0.000 description 4
- 238000002523 gelfiltration Methods 0.000 description 4
- 229940127121 immunoconjugate Drugs 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 229960001922 sodium perborate Drugs 0.000 description 4
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 239000001166 ammonium sulphate Substances 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000005281 excited state Effects 0.000 description 2
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 2
- -1 iron protoporphyrin compounds Chemical class 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- BMUDPLZKKRQECS-UHFFFAOYSA-K 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid iron(3+) hydroxide Chemical class [OH-].[Fe+3].[N-]1C2=C(C)C(CCC(O)=O)=C1C=C([N-]1)C(CCC(O)=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 BMUDPLZKKRQECS-UHFFFAOYSA-K 0.000 description 1
- OROGUZVNAFJPHA-UHFFFAOYSA-N 3-hydroxy-2,4-dimethyl-2H-thiophen-5-one Chemical compound CC1SC(=O)C(C)=C1O OROGUZVNAFJPHA-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- PNTHAHMQGFVKMP-UHFFFAOYSA-M [Fe]N1C(=O)C=CC1=O.N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 Chemical compound [Fe]N1C(=O)C=CC1=O.N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 PNTHAHMQGFVKMP-UHFFFAOYSA-M 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 229940098197 human immunoglobulin g Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000013469 light sensitivity Diseases 0.000 description 1
- KNJDBYZZKAZQNG-UHFFFAOYSA-N lucigenin Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.C12=CC=CC=C2[N+](C)=C(C=CC=C2)C2=C1C1=C(C=CC=C2)C2=[N+](C)C2=CC=CC=C12 KNJDBYZZKAZQNG-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- NINOYJQVULROET-UHFFFAOYSA-N n,n-dimethylethenamine Chemical group CN(C)C=C NINOYJQVULROET-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
A conjugate for use in the detection and quantification of antibodies and antigens in body fluids comprises an immunologically active compound having attached to it a tag which is a metallo porphyrin and is capable of catalyzing a chemiluminescent reaction. The conjugate may be an antibody or an antigen to which a metallo porphyrin tag is attached and preferably comprises immunoglobulin to which haemoglobin is attached through a bifunctional linking agent. The tag may be derived from haemoglobin, myoglobin or cytochrome C. In use of the conjugate in chemiluminescence immunoassay, a reaction product carrying the tag may be mixed with luminol-perborate solution and the light output measured.
Description
SPECIFICATION
A conjugate for use in an immunoassay procedure
This invention relates to conjugates for use in immunoassay procedures for the detection and
quantification of anitbodies and antigens (including haptens) and other substances present in small
amounts in body fluids.
Various test systems have been developed for the detection and quantification of antibodies,
antigens and other substances present in small amounts of body fluids. The most sensitive are
immunoassay procedures which take advantage of the fact that an antibody binds specifically to its
antigen and the reaction obeys the mass action law, Ab + Ag - AbAg.
Several immunoassay techniques are currently employed which can be classified by their binding
characteristics. The most common utilise competetive and sandwich binding. Regardless of the technique a conjugate tagged for detection must be employed. The most widely used tags are
radioisotopes and the procedure is called radioimmunoassay (RIA). Other procedures using different tags include enzyme immunoassay (EIA) and fluorescent immunoassay (FIA).
Radioimmunoassays using as tags the radioactive isotopes i2S,i4 or 3H presently command the major share of the market because of their extremely high sensitivities, that is, their ability to detect
10-15 moles or less of antigen or antibody. Despite their high sensitivity, RIA's suffer from the following disadvantages: (1) the beta and gamma counters required for the readout system are expensive and
require expensive upkeep by highly trained service persons, (2) supervisory personnel must be highly trained and licensed by the government for work with radioisotopes, (3) because of the radioactivity
RIA's are effectively prohibited in many countries outside of the United States, (4) the high radioactivity
required for an appropriate signal requires the use of short-lived isotopes, thus requiring the frequent
resynthesis of tagged compounds, and (5) the short lives means that the signal to concentration of tag
ratio is continually and rapidly changing requiring frequent recalibration for each assay.
Enzyme immunoassays require the use of complex biological materials with retention of their
native activity. The procedures themselves are time consuming due to the slow nature of the readout
reaction and do not always yield requisite high sensitivities.
Fluorescent systems have slightly lower sensitivity limits than radioimmunoassay systems and
require long incubation periods. In addition, high and variable blanks are often encountered.
Chemiluminescence refers to light produced as a direct result of chemical change. It involves the transformation of the free energy of a chemical reaction into light energy. The chemical reaction must
release sufficient energy to populate an excited energy state; the reaction pathway must favour the formation of the excited state product; and the excited state product must be capable of emitting a
photon itself for transferring its energy to another molecule that can emit.
A well-known, highly efficient chemiluminescent reaction is the oxidation of luminol (5-amino2,3-dihydrophthalazine-1 ,4-dione) in a basic solution. The most frequently used oxidant is hydrogen
peroxide in the presence of a catalyst such as Fe(CN)36, Cu(ll), and Co(ll). Other oxidants include perborate, hypochlorite, iodine, permanganate and oxygen.
Chemiluminescence has been utilised in immunoassay procedures. United States Patent
Specification No. 4 104 029 discloses a procedure for the assay of pharmacologically immunologically
and biochemically active compounds in biological fluids in which a ligand is labelled with a chemiluminescent material such as luminol. In addition, it is known that iron and specifically iron protoporphyrin compounds react with luminol in the presence of hydrogen peroxide or sodium perborate and a base to give an excited species which emits light with with high efficiency, (see Ewetz
and Thore's'Factors Affecting the Specificity of the Luminol Reaction with Hematin Compounds,
Analytical Biochemistry, 71, 564570 (1976)).
The present invention seeks to provide a fast, sensitive and objective immunoassay for antigens or antibodies, to eliminate radioisotope hazards and the need for highly trained personnel to eliminate the
need for special facilities associated with isotope work, to utilise only simple instrumentation and
provide fast readout and high sensitivity (up to 10-15 mole detection), and to provide a long-lived tagged
immunoreagent which is of relatively low cost and of ready availability. Because of its universal
reactivity, a conjugate according to the present invention is applicable to a number of different assay
procedures.
According to one aspect of the present invention, there is provided a conjugate for use in an immunoassay procedure in which the conjugate is detectable by chemiluminescence, the conjugate comprising an immunological active compound to which a metallic porphyrin tag is attached. Any antibody or binding partner for an antibody including antigens and haptens may be used. Antibodies raised in animal species such as goats and rabbits are particularly suitable. Antigens such as hormones and blood plasma proteins and haptens are suitable. Immunoglobulin and particularly IgG is particularly useful because of its availability and because it acts as both an antigen and antibody. Antigens which naturally contain iron porphyrin such as haemoglobin, myoglobin and cytochrome C may be used as the entire conjugate.
Because the tag functions as a catalyst rather than a reactant, each tag produces a plurality of photons whereas a luminol tag would only produce a single photon. This results in two advantages, namely greater sensitivity and prolonged emission.
The metallo porphyrin tag may be a molecule containing a metallo porphyrin and particularly a protein containing iron porphyrin. It may be iron porphyrin itself such as hemin. Haemoglobin, myoglobin, cytochrome C and catalase are suitable.
The metallo porphyrin tag is attached to the antigen or antibody by means of known bifunctional linking agents such as syanuric chloride, acrylyl chloride, and glutaraldehyde.
The conjugate is useful in various immunoassay procedures to determine the concentration of an unknown in an analyte. Typically such procedures use a reagent, an analyte and a conjugate. In a competitive assay the reagent which is generally attached to a solid phase such as nylon or polystyrene must be a binding partner for the conjugate. The analyte may be a binding partner for the conjugate or the reagent but not both. In a sandwich type assay the conjugate and the reagent cannot be binding partners for each other. Both are binding partners for the analyte. The binding reactions can be shown graphically as follows:
A.Competitive Assay
Reagent Analyte Conjugate (Solid Phase) -Ab + Ag-Tag (1) j -Ab + Abs + Ag-Tag + Ab5 + Ag-Tag -Ab - AS-TaS (2) -Ab + Ags + Ag-Tag ;b > + =1 -Ab - Ag, B. Sandwich Assay (3) -Ab Ag, - Ab'-Tag (3) a -Ab + Ag5 + Ab'-Tag 'Tage , Thus in a competitive assay the greater the amount of the unknown (Abs or Ags) in the analyte, the less conjugate which can react with the reagent. In a sandwich assay the opposite is true.As the amount of the unknown in the analyte increases the amount of conjugate which reacts with the reagent increases.
To determine the amount of the unknown in the analyte, the reagent is separated from the remaining reactants. It is for ease in separation that the reagent is generally attached to a solid phase.
After separation including thorough washing to make certain no unreacted conjugate remains, the reagent is mixed with a chemiluminescent reactant. Luminol is preferred because of its efficiency. Other chemiluminescent substances which may be used include tetrabis (dimethylamino) ethylene, luciferin, lucigenin (dimethyl diacridinum nitrate) and oxalyl chloride. As an oxidant sodium perborate is preferred.
However, other known catalysts may be used.
The metallic component of the tag in the conjugate will catalyze the chemiluminescent reaction.
The amount of light emission recorded in a standard manner gives a quantitative determination of the amount of conjugate which is bound to the reagent and, hence, the amount of unknown in the analyte.
The following examples serve to illustrate the invention but are not to be regarded as limiting:
EXAMPLE 1
Competitive Assay of Human Immunoglobulin G
A. Preparation of Reagent {Solid Phase)
Nylon mesh was partially hydrolysed by treating in 2 NHCI at 370C overnight. The nylon was washed free of acid with 0.01 MNa2CO3, pH 10, and washed with water. The nylon was placed in a solution of 400 mg of 1 ethyl-3(3-dimethylaminopropyl)-carbodiimide in water, pH 3.7. The pH was maintained between 3.5 and 3.8. The activation reaction was continued at room temperature until the consumption of acid ceased. The nylon was rapidly washed two times with dilute HCI (pH 3.4 to 3.8).
Human immunoglobulin, dissolved in 50 mM NaCI, pH 3.4, to 10 mg of protein per ml, was added to the washed activated nylon and the pH was gradually raised to pH 7 over 60 minutes. The attachment reaction was allowed to proceed for 60 minutes at pH 7. The pH was adjusted to 7.2 to 7.4 and the composition was incubated for 4 hours.
The nylon was washed according to the following sequence: 2 M NaCI, two times; water; 10 mM phosphate buffer, pH 7.35, containing 0.3 M NaCI, 0.2% bovine serum albumin and 0.1% Tween 80, two times; phosphate buffered saline, two times; and water. The washed nylon-immunoglobulin reagent was air dried and used in 1 cm2 pieces as the solid phase in immunoassays.
B. Preparation of Conjugate
An iron porphyrin-antibody conjugate was prepared as follows: Goat anti-human serum was partially purified by precipitation with ammonium sulphate, and dialyzed against saline. To 2 ml of this solution (100 mg protein), 30 mg of sodium bicarbonate and 2 ml of water was added. A solution of cyanuric chloride in dioxane, 4 mg/ml, was added to the rapidly stirring solution of globulin. After 2 minutes a solution of 1 00 mg of haemoglobin in 4 ml of water was added and the binding reaction was allowed to proceed for 18 hours at 250C.
After reaction, the mixture was charged onto a 1.5 x 100 cm column of polyacrylamide gel, Bio
Gel P-200 (100-200 mesh) and elution performed with 0.002 N phosphate buffer, pH 7.0, containing 0.05 M sodium chloride and 0.02% sodium azide. In this way any unreacted haemoglobin could be removed from the conjugate. The fractions containing both haemoglobin and antibody activity were pooled and used as the conjugate.
C. Preparation of Chemiluminescent Reactants
The chemiluminescent readout measurements were performed on an Aminoco Chem-Glo
Photometer.
The following solutions were used for CL analyses:
Luminol Stock Solution. To 2.00 mg of luminol and 32 mg of glucose was added 4 ml of 0.1 N sodium hydroxide. After complete dissolution of the luminol, the solution was made up to 100 ml with water. The solution was stored at 40C.
Luminol Working Solution. Each working day, 1.00 ml of the above solution and 10 ml of 0.1 N sodium hydroxide was made up to 100 ml with water.
Perborate Solution. Each working day, 77 mg of sodium perborate was dissolved in 100 ml of water.
Analyses of chemiluminescence were carried out as follows:
In a shell vial was placed 0.5 ml of the test solution, made up in the luminol stock solution as described above. This was placed in the sample compartment of the Chem-Glo-Meter. To this was then added 0.1 ml of the perborate solution. The light output was taken as the maximum pen deflection shewn on the recorder. In most cases, an average of the results of three sample injections was used.
D. Assay Procedure
An immunoassay was performed with the human immunoglobulin-nylon solid phase and the iron porphyrin-antibody conjugate.
Nylon discs (surface area = 1 sq. cm) were incubated with 0.4 ml of conjugate at various dilutions plus 0.1 ml of phosphate buffered saline or 0.4 ml of conjugate at various dilutions plus 0.1 ml of a solution of human immunoglobulin. All dilutions of conjugate and human immunoglobulin were made with phosphate buffered saline. After incubation for 60 minutes at room temperature, the solutions were aspirated and the nylon discs were washed successively with 4.5 ml of 0.5% BSA-O.05% Tween
20, 2 M NaCI-pH 9.0, BSA-Tween-20 and two times with 0.1 M phosphate pH 6.1 buffer.
After washing, individual discs were eluted with a luminol working solution. For this purpose, 3.0 ml of the luminol working solution was added to each tube and the tube plus contents was sonicated for five minutes. A 500 yl aliquot of the solution was introduced into a vial, placed in an appropriate instrument such as the Aminco Chem-Glo Photometer, reacted with a solution of sodium perborate and the resultant light output was recorded.
E. Results
The results obtained are presented in Table I. Inhibition of conjugate uptake onto the insoluble nylon-human immunoglobulin is seen over a wide range of conjugate concentration and competing immunoglobulin concentrations.
TABLE I
Soluble
Nylon Conjugate Immunoglobulin Relative
Sheet Conc. (mg/ml) Added (,up) Light Intensity
A 0.1 0 4,300
B 0.1 0.1 2,885
C 0.04 0 1,995
D 0.04 0.1 1,245
E 0.04 100.0 202
F 0.02 0 1,490
G 0.02 0.1 364
H 0.01 0 1,125
0.01 0.1 182
J 0.000 0 52
EXAMPLE II
Preparation of Haemoglobin-Antibody Conjugates
A series of haemoglobin-antibody conjugates were prepared as shown in Table II.
TABLE II
Activation Step Binding Step Product Composition
Cyanuric a
Volume Chloride Time Temp. Hemoglobin Hemoglobin
Example mi mg sec. OC. mg Immunoglobulin IIA 4 4 120 25 400 0.83
B 4 8 120 25 400 0.65
C 4 4 120 25 100 0.63
D 4 4 600 25 100 0.74
E 4 8 120 25 100 Insoluble products
F 4 2 120 25 100 0.49
G 4 1 120 25 100 0.19
H 10 4 10 0 100 1.34
10 4 1 0 100 1.07
J 10 2 10 0 100 0.90
K 20 4 10 0 100 1.05
L 4 4 10 0 100 1.73 a
Molar ratio, determined from the amount of free haemoglobin and the amount of haemoglobin in the oligomer fraction as shown by analysis of gel filtration column as in Example I
Conjugates were tested and both had CL catalyzing and immunological properties.Results similar
to Example I were obtained in the immunoassay with conjugates Il-C and lI-L and nylon bound
antibody from Example I.
EXAMPLE II
Competitive Assay of Immunoglobulin in Human Serum
Nylon bound human immunoglobulin, as prepared in Example I, and haemoglobulin conjugated to
anti-immunoglobulin, Example Il-C, were incubated in the presence and absence of human serum.
Reduced light output was observed in the presence of human serum.
EXAMPLE IV
DirectAssay of human Haemoglobin
Antibody to human haemoglobin was partially purified by ammonium sulphate precipitation;
dissolved to 12,ug protein/ml of 0.05 M sodium carbonate, pH 9.6 The antibody was adsorbed onto
polystyrene tubes Falcon Number 2054) for 1 hour at 370C. The solid phase antibody tubes were
treated with 0.5% bovine serum albumin for 30 minutes at 370C. and washed 2 times with 0.2% bovine
serum albumin containing 0.5% Tween in buffered saline. The antibody tubes were incubated in the
absence and in the presence of human haemoglobin for 30 minutes at room temperature and washed with the albumin-Tween buffered saline 3 times and chemiluminescence was measured as in Example
Light emission was higher when haemoglobin was added to the tubes and proportional to the amount of haemoglobin present.
EXAMPLE V Immun.oassay of Myoglobin Antibody to myoglobin was adsorbed to polystyrene and immunoassays were performed as in
Example IV with similar results.
EXAMPLE VI
Sandwich Assay of Chorionic Gonadotropin
A. Preparation of reagent Goat antibody to human chorionic gonadotropin (HCG) bound to nylon beads: partial hydrolysis of the nylon was accomplished with N HCI for 2 hours. The beads were washed and additional carboxyl groups were introduced by allowing the beads to react with an excess of maleic anhydride at a constant pH between pH 8 and 9 for 1 hour. The beads were washed and the carboxyl groups were activated with 2 g of water soluble carbodiimide at a constant pH of 4.5 to 5.2 for 30 minutes. Excess carbodiimide was removed and goat anti-HCG was bound to the beads for 3 hours at room temperature followed by 1 8 hours at 40C.The antibody beads were treated with 0.2% bovine serum albumin in buffered saline, washed and stored in bovine serum albumin in buffered saline at 40C prior to use.
B. Preparation of Conjugate
An iron porphyrin containing peptide derived from cytochome C was prepared by pepsin digestion of cytochrome C, followed by acid precipitation and dialysis. This peptide, demonstrated a higher
chemiluminescent yield per porphyrin molecule than cytochrome C itself. Goat antibody to HCG was
partially purified by ammonium sulphate precipitation and digested with pepsin to produce (Fab')2
fragments which were purified by gel filtration on Sephadex O75 column. Thiol groups were introduced
onto the antibody fragment using N-acetyhomocysteine thiolactone and the thiolated antibody
fragment was separated from excess thiolating reagent by gel filtration over a Sephadex G-25 column.
The iron porphyrin peptide was activated for conjunction to the thiolated antibody fragment by
introduction of maleimide moieties using m-maleimidobenzoyl N-hydroxysuccinimide ester followed by
Sephadex G-25 filtration. The conjugate was prepared by mixing thiolated antibody fragment and
maleimido-iron porphyrin peptide for one hour at room temperature followed by gel filtration on a
Sephadex G-75 column.
Immunoassays using antibody to HCG bound to nylon beads and iron porphyrin conjugated to
antibody fragments derived from antibody to HCG were performed.
C. Assay Procedure
Nylon beads conjugated with antihuman lgG were placed in glass tubes and incubated 30 minutes
at 370C with 2.5 I.U. of HCG in a solution of 0.2% bovine serum albumin in phosphate buffered saline or
phosphate buffered saline alone. The solutions were then aspirated and the beads were washed with
0.5 M HEPES, 0.5 M NaCI, pH 7.2 and then incubated for 30 minutes at 370C with various dilutions of the conjugate in . & 0.5 M HEPES, 0.1 5 M NaCI, pH 7.2 buffer. After incubation at 370C for 30 minutes, the beads were once again washed and the beads were eluted with 0.5 ml of 0.10/0 sodium dodecyl
sulphate for five minutes. Luminol was added and light emission was measured as in Example I. Table Ill
shows results typical of this double antibody sandwich assay for an antigen.
TABLE Ill
Dilution of Relative
Tube HCG Added Conjugate Light Sensitivity
1 + 1:5 61.1
2 + 1:10 39.0
3 + 1:25 16.1
4 + 1:50 3.25
5 + 1:100 2.40
6 + 1.21
7 - 1:5 19.5
8 - 1:10 4.81
9 - 1:25 3.56
10 - 1:50 2.34
11 - 1:100 2.21
12 - 1.63
The data shows increased CL indicating increased uptake of conjugate in the presence of HCG over a wide range of conjugate dilutions.
Claims (11)
1. A conjugate for use in an immunoassay procedure in which the conjugate is detectable by chemiluminescence, the conjugate comprising an immunological active compound to which a metallo porphyrin tag is attached.
2. A conjugate for use in an immunoassay procedure in which the conjugate is detectable by chemiluminescence, the conjugate comprising an antibody or a binding partner for an antibody to which a metallo porphyrin tag is attached.
3. A conjugate for use in an immunoassay procedure in which the conjugate is detectable by chemiluminescence, the conjugate comprising an antibody to which an iron porphyrin tag is attached.
4. A conjugate for use in an immunoassay procedure in which the conjugate is detectable by chemiluminescence, the conjugate comprising an antigen to which an iron porphyrin tag is attached.
5. A conjugate for use in an immunoassay procedure in which the conjugate is detectable by chemiluminescence, the conjugate comprising a protein to which a metallo porphyrin tag is attached.
6. A conjugate as claimed in claim 5 in which said protein is immunoglobulin or a hormone.
7. A conjugate as claimed in claim 5 or 6 in which the tag is an iron porphyrin.
8. A conjugate as claimed in claim 8 in which the iron prophyrin is derived from haemoglobin or myoglobin, or cytochrome C.
9. A conjugate for use in the detection and quantification of antibodies and antigens in body fluids by immunoassay procedures, said conjugate being capable of reacting with an antigen or an antibody or both and including a tag capable of catalyzing a chemiluminescent reaction comprising an antigen or an antibody to which a metallo porphyrin tag is attached.
1 0. A conjugate for use in the detection and quantification of antibodies and antigens in body fluids by immunoassay procedures, said conjugate being capable of reacting with an antigen or an antibody or both and including a tag capable of catalyzing a chemiluminescent reaction comprising immunoglobulin to which iron porphyrin derived from haemoglobin is attached.
11. A conjugate substantially as herein described with reference to the Examples.
11. A conjugate substantially as herein described with reference to the Examples.
12. An immunoassay procedure in which a conjugate as claimed in any preceding claim is detected by chemiluminescence.
13. An immunoassay procedure substantially as herein described with reference to the Examples.
New claims or amendments to claims filed on 28 Jan 1981
Superseded claims 1 to 13
New or amended claims:
1. A conjugate for use in an immunoassay procedure in which the conjugate is detectable by chemiluminescence, the conjugate comprising an immunological active compound attached to a metallo porphyrin tag with a bifunctional linking agent.
2. A conjugate as claimed in claim 1 in which the bifunctional linking agent is any one of cyanuric chloride, acrylyl chloride and glutaraldehyde.
3. A conjugate as claimed in claim 1 or 2 in which said immunological active compound is an antibody or a binding partner for an antibody.
4. A conjugate as claimed in claim 3 in which said binding partner for an antibody is an antigen.
5. A conjugate as claimed in claim 1 or 2 in which said immunological active compound is a protein.
6. A conjugate as claimed in claim 6 in which said protein is immunoglobulin.
7. A conjugate as claimed in claim 6 in which said protein is a hormone.
8. A conjugate as claimed in any preceding claim in which said metallo porphyrin is iron porphyrin.
9. A conjugate as claimed in claim 8 in which said iron porphyrin is hemoglobin or myoglobin or cytochrome C.
10. An immunoassay procedure comprising: treating an unknown immunologically active agent with a conjugate comprising an immunologically active compound to which a metallo porphyrin tag has been attached to form a complex; treating the complex with a chemiluminescent reactant; and measuring the amount of light emitted.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8560179A | 1979-10-17 | 1979-10-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB2063469A true GB2063469A (en) | 1981-06-03 |
| GB2063469B GB2063469B (en) | 1983-07-20 |
Family
ID=22192713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB8033401A Expired GB2063469B (en) | 1979-10-17 | 1980-10-16 | Conjugate for use in an immunoassay procedure |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JPS5696249A (en) |
| CA (1) | CA1135620A (en) |
| DE (1) | DE3039157A1 (en) |
| FR (1) | FR2468125B1 (en) |
| GB (1) | GB2063469B (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0071991A3 (en) * | 1981-08-10 | 1983-09-07 | Bio-Diagnostics, Inc. | Improved fluoro immuno assay system |
| US4707454A (en) * | 1981-08-10 | 1987-11-17 | Bio-Diagnostics, Inc. | Fluorescent chlorophyll labeled assay reagents |
| WO1989001630A1 (en) * | 1987-08-12 | 1989-02-23 | Nemeth Peter | Procedure for relieving cell mixtures and tissues of unwanted populations |
| GB2233451A (en) * | 1989-06-27 | 1991-01-09 | Tropix Inc | Chemiluminescent enhancement |
| US5145772A (en) * | 1986-07-24 | 1992-09-08 | Tropix, Inc. | Chemiluminescence enhancement of enzyme-activated decomposition of enzymatically cleavable chemiluminescent 1,2-dioxetanes |
| EP0812920A1 (en) * | 1996-06-14 | 1997-12-17 | Packard Instrument B.V. | Use of porphyrins in instrumental detection methods |
| WO1998054578A1 (en) * | 1997-05-29 | 1998-12-03 | Bio-Rad Laboratories, Inc. | Chemiluminescent hemoglobin assay |
| US6001573A (en) * | 1996-06-14 | 1999-12-14 | Packard Bioscience B.V. | Use of porphyrins as a universal label |
| RU2196328C1 (en) * | 2001-05-04 | 2003-01-10 | Корякин Софрон Павлович | Application of a plotting board immunoenzymatic analyzer as a hemoglobinometer |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0711522B2 (en) * | 1989-09-13 | 1995-02-08 | 工業技術院長 | Chemically amplified chemiluminescence immunoassay |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2244170A1 (en) * | 1973-09-14 | 1975-04-11 | Sibiem | Colorimetric assay of biological material - by fixing colouring matter to the test material, and optically assaying soln |
| US4181650A (en) * | 1975-08-25 | 1980-01-01 | Maier Charles L Jr | Procedure for the assay of pharmacologically immunologically and biochemically active compounds in biological fluids |
| US4220450A (en) * | 1978-04-05 | 1980-09-02 | Syva Company | Chemically induced fluorescence immunoassay |
-
1980
- 1980-10-16 GB GB8033401A patent/GB2063469B/en not_active Expired
- 1980-10-16 DE DE19803039157 patent/DE3039157A1/en not_active Withdrawn
- 1980-10-16 CA CA000362570A patent/CA1135620A/en not_active Expired
- 1980-10-17 FR FR8022282A patent/FR2468125B1/en not_active Expired
- 1980-10-17 JP JP14451680A patent/JPS5696249A/en active Pending
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0071991A3 (en) * | 1981-08-10 | 1983-09-07 | Bio-Diagnostics, Inc. | Improved fluoro immuno assay system |
| US4707454A (en) * | 1981-08-10 | 1987-11-17 | Bio-Diagnostics, Inc. | Fluorescent chlorophyll labeled assay reagents |
| US5145772A (en) * | 1986-07-24 | 1992-09-08 | Tropix, Inc. | Chemiluminescence enhancement of enzyme-activated decomposition of enzymatically cleavable chemiluminescent 1,2-dioxetanes |
| WO1989001630A1 (en) * | 1987-08-12 | 1989-02-23 | Nemeth Peter | Procedure for relieving cell mixtures and tissues of unwanted populations |
| GB2233451A (en) * | 1989-06-27 | 1991-01-09 | Tropix Inc | Chemiluminescent enhancement |
| GB2233451B (en) * | 1989-06-27 | 1993-09-15 | Tropix Inc | Chemiluminescence enhancement |
| EP0812920A1 (en) * | 1996-06-14 | 1997-12-17 | Packard Instrument B.V. | Use of porphyrins in instrumental detection methods |
| US5998128A (en) * | 1996-06-14 | 1999-12-07 | Packard Instrument B.V. | Use of porphyrins in instrumental detection methods |
| US6001573A (en) * | 1996-06-14 | 1999-12-14 | Packard Bioscience B.V. | Use of porphyrins as a universal label |
| WO1998054578A1 (en) * | 1997-05-29 | 1998-12-03 | Bio-Rad Laboratories, Inc. | Chemiluminescent hemoglobin assay |
| RU2196328C1 (en) * | 2001-05-04 | 2003-01-10 | Корякин Софрон Павлович | Application of a plotting board immunoenzymatic analyzer as a hemoglobinometer |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5696249A (en) | 1981-08-04 |
| CA1135620A (en) | 1982-11-16 |
| FR2468125A1 (en) | 1981-04-30 |
| DE3039157A1 (en) | 1981-08-27 |
| FR2468125B1 (en) | 1985-08-23 |
| GB2063469B (en) | 1983-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4375972A (en) | Heterogeneous chemiluminescent immunoassays utilizing metallo porphyrin tag | |
| US4478817A (en) | Detecting or quantifying substances using labelling techniques | |
| Blake et al. | Use of enzymes in immunoassay techniques. A review | |
| EP0594772B1 (en) | Water-soluble, polymer-based reagents and conjugates comprising moieties derived from divinyl sulfone | |
| US5543332A (en) | Water-soluble, polymer-based reagents and conjugates comprising moieties derived from divinyl sulfone | |
| EP0087959B1 (en) | Enhanced luminescent and luminometric assay | |
| US4859583A (en) | Chemiluminescent immunochemical technique for low molecular weight antigens | |
| US4959306A (en) | Labeling design for a binding assay reagent | |
| JPS60226900A (en) | Nucleic acid-protein complex | |
| Johannsson | Heterogeneous enzyme immunoassay | |
| EP0640216B1 (en) | Separation method | |
| CA1135620A (en) | Immunological compound attached to metallo-porphyrin tag | |
| US5672475A (en) | Mixed luminescent conjugate test | |
| CA2164767C (en) | Immunoassays for haptens and hapten tracer-antibody complex which can be used therefor, and process for the preparation thereof | |
| Kato et al. | Fluorophotometric enzyme immunoassay of thyroid-stimulating hormone | |
| US5196349A (en) | Immunoassays for thyroid hormones using thyroglobulin | |
| JPH0456257B2 (en) | ||
| JPH02124462A (en) | Improved immunity measuring method | |
| AU582341B2 (en) | Assay for immobilized reporter groups | |
| EP0480361A2 (en) | Quantitation by chemiluminescence using photosenstive substance | |
| JPH0346565A (en) | Enzyme immunoassay utilizing magnetic material | |
| JP3792899B2 (en) | Chemiluminescent enzyme immunoassay method | |
| JP4028645B2 (en) | Chemiluminescent enzyme immunoassay method | |
| KR960016337B1 (en) | Reagent kit for use in sandwich immunoassay | |
| Haasnoot et al. | Immunochemical and receptor technologies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PCNP | Patent ceased through non-payment of renewal fee |